

The Cartagena Protocol on Biosafety is a legally binding protocol to the Convention on Biological Diversity (CBD). It was named in honor of Cartagena, Colombia, where negotiations were expected to conclude in February 1999. One year later, on January 29, 2000, the Protocol was finalized and adopted in Montreal, Canada by unanimous consent with 135 countries present.

## WHAT IS THE BIOSAFETY PROTOCOL?



O. GUTIERREZ PHOTO



MICROSOFT CORP. PHOTO

### Capacity Building

The Protocol promotes international cooperation to help developing countries acquire resources and capacity to use biotechnology safely and regulate it efficiently. It does this by encouraging member governments to assist with scientific and technical training to promote the transfer of technology, knowledge and financial resources. Governments are also expected to facilitate greater involvement of the private sector.

### Public Awareness

Member governments must commit themselves to promoting public awareness, insuring public access to information, and public consultation. The Protocol recognizes that national measures are important to make its procedures effective. Nations must also take measures to prevent illegal shipments or accidental releases of LMOs.

### WHAT IS THE PROTOCOL'S OBJECTIVE?

Article 1 of the Protocol states that it aims to "contribute to ensuring an adequate level of protection in the field of the safe transfer, handling and use of living modified organisms resulting from modern biotechnology that may have adverse effects on the conservation and sustainable use of biological diversity, and specifically focusing on health, and specifically focusing on taking also into account risks to human sustainable use of biological diversity, reflecting the worldwide satisfaction of growers. While advances in biotechnology have great potential to improve human well-being, the technology must be developed with adequate safety measures. The Cartagena Protocol on Biosafety is a legally binding global protocol that seeks to transfer, handling and use of living modified organisms (LMOs) created through modern biotechnology.

### WHAT DOES THE PROTOCOL COVER?

The Protocol covers the "transboundary movement, transit, handling and use of LMOs, which are pharmaceuticals for humans that are addressed by other relevant international agreements or organizations (e.g. paper from GM trees)

- Products derived from LMOs

It does not cover:

- all living modified organisms that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health";



USDA PHOTO

### USE OF TERMS

#### Living modified organism (LMO)

Any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology

#### Modern biotechnology

The application of

- In vitro* nucleic acid techniques, including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles or
- Fusion of cells beyond the taxonomic family,

that overcome natural physiological reproductive or recombination barriers and that are not techniques used in traditional breeding and selection. (<http://www.biodiv.org/biosafety/protocol.asp>)

### USEFUL WEBSITES

Biosafety Protocol  
(<http://www.biodiv.org/biosafety>)  
Biosafety Clearing House  
(<http://bch.biodiv.org/pilot>)

Pocket Ks are Pockets of Knowledge, packaged information on crop biotechnology products and related issues available at your fingertips. They are produced by the Global Knowledge Center on Crop Biotechnology (<http://www.isaaa.org/kc>). For more information, please contact the International Service for the Acquisition of Agri-biotech Applications (ISAAA) SEAsiaCenter c/o IRRRI, DAPO Box 7777, Metro Manila, Philippines  
Tel: +63-2-845 0563  
Fax: +63-2-845 0606  
E-mail: [knowledge.center@isaaa.org](mailto:knowledge.center@isaaa.org)

First Printing, July 2002  
Revised July 2004



INTERNATIONAL SERVICE  
FOR THE ACQUISITION  
OF AGRIBIOTECH  
APPLICATIONS

In 1994, the first genetically modified food crop, Calgene's Flavor-Savr™ tomato, was produced and consumed in an industrialized country. Since that time, genetically modified (GM) crops have been rapidly adopted worldwide reflecting the satisfaction of growers. While advances in biotechnology have great potential to improve human well-being, the technology must be developed with adequate safety measures. The Cartagena Protocol on Biosafety is a legally binding global protocol that seeks to transfer, handling and use of living modified organisms (LMOs) created through modern biotechnology.



MICROSOFT CORP. PHOTO



## Cartagena Protocol on Biosafety

Global Knowledge Center  
on Crop Biotechnology

## WHAT DOES THE BIOSAFETY PROTOCOL DO?

- It assists developing countries in building their capacity for managing modern biotechnology
- It creates an advanced informed agreement (AIA) procedure that requires exporters to seek consent from importing countries before the first shipment of LMOs meant to be introduced into the environment (e.g. seeds for planting, fish for release, and microorganisms for bioremediation)
- It establishes an internet-based "Biosafety Clearing-House" to help countries exchange scientific, technical, environmental and legal information about LMOs.
- It requires bulk shipments of LMO commodities, such as corn or soybeans that are intended to be used as food, feed or for processing, to be



USDA PHOTO

accompanied by documentation stating that such shipments "may contain" LMOs and are "not intended for intentional introduction into the environment".

- The Protocol includes a clause that makes clear the Parties' intent that the agreement does not alter the rights and obligations of governments under the World Trade Organization (WTO) or other existing international agreements.

## WHAT DOES THE BIOSAFETY PROTOCOL NOT DO?

- The Protocol does not address food safety issues. This is addressed by experts in other international fora.
- The Protocol does not require segregation of bulk shipments of commodities that may contain living modified organisms.
- It does not require consumer product labeling.
- It does not subject shipments of bulk commodities to the Protocol's AIA procedure.



LORI ALDEN PHOTO

## KEY FEATURES OF THE PROTOCOL

### Advanced Informed Agreement (AIA)

The Protocol's main mechanism is its Advanced Informed Agreement (AIA) requirement. It is a procedure that must be followed before the first intentional transboundary movement of an LMO into the environment of the importing country. The exporter must provide a notification to the importing country containing detailed information about the LMO, previous risk assessments of the LMO and its regulatory status in the exporting country. The importing country must acknowledge receiving the information within 90 days and whether the notifier should proceed under a domestic regulatory system or under the Protocol procedure. In either case, the importing country must decide whether to allow the import, with or without conditions or deny it within 270 days.

What is not subject to the AIA requirement?

- Consecutive shipments. The Protocol's AIA only covers first time shipments.
- LMOs not intended for release into the environment such as commodities, LMOs in transit, and LMOs destined for contained use.



MICROSOFT CORP. PHOTO

### Biosafety Clearing-House (BCH)

The BCH is a website administered by the Secretariat to the Convention (<http://bch.biodiv.org>). It was established to: 1) facilitate the exchange of scientific, technical, environmental and legal information on, and experience with LMOs; and 2) assist Parties to implement the Protocol. Examples of information contained in the BCH include: any existing laws, regulations, or guidelines for implementation of the Protocol, summaries of risk assessments or environmental reviews of LMOs, and final decisions regarding the importation or release of LMOs.

### Risk Assessment

The Protocol requires that decisions on proposed imports be based on risk assessments.

- Risk assessments must be undertaken in a scientific manner based on recognized risk assessment techniques, taking into account advice and guidelines developed by relevant international organizations.
  - Lack of scientific knowledge or scientific consensus must not necessarily be interpreted as indicating a particular level or risk, an absence or risk, or an acceptable risk.
  - Risks associated with LMOs or products thereof should be considered in the context of risks posed by the non-modified recipients or parental organisms in the likely potential receiving environment.



ISAAA PHOTO

Risk assessment should be carried out on a case by case basis.